ArticleUnited European gastroenterology journal2020
Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort.
Article in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.Alimentary pharmacology & therapeutics · 2023Pooled it
- Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.Journal of Crohn's & colitis · 2024Trial
- Efficacy of the Panax Notoginseng Ejiao Suppository in the Treatment of Patients with Ulcerative Proctitis and Its Effect on Inflammatory Response and Immune Function.Disease markers · 2022Trial
- The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Long-Term Comparative Outcomes of TNF-α Antagonists vs. Vedolizumab as First-Line Biologic Therapy for Refractory Ulcerative Proctitis: A Propensity-Matched Study.Biomedicines · 2026Article
- Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States.Therapeutic advances in gastroenterology · 2026Article
- Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study.Inflammatory bowel diseases · 2025Article
- Clinical features and current treatment approach to ulcerative proctitis.Translational gastroenterology and hepatology · 2025Review
- Separating Infectious Proctitis from Inflammatory Bowel Disease-A Common Clinical Conundrum.Microorganisms · 2024Review
- Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.Therapeutic advances in gastroenterology · 2024Article
- Delphi consensus survey: the opinions of patients living with refractory ulcerative proctitis and the health care professionals who care for them.BMJ open gastroenterology · 2023Article
- Seronegative spondyloarthropathy-associated inflammatory bowel disease.World journal of gastroenterology · 2023Review
- When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.Current research in pharmacology and drug discovery · 2022Review
- Positioning biologics in the treatment of IBD: A practical guideCurrent research in pharmacology and drug discovery · 2022Review
- Orphan patients with inflammatory bowel disease - when we treat beyond evidence.World journal of gastroenterology · 2021Review
- Long-term outcome of ulcerative proctitis.United European gastroenterology journal · 2020Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong-term outcomes of patients with ulcerative proctitis (UP) have been poorly investigated, since these patients are excluded from participation in randomized controlled clinical trials.
objectiveThe aim of this study was to investigate the prognostic and therapeutic long-term outcomes of patients with UP.
methodsA retrospective study of patients with UP followed at our referral centre between 1 January 1998 and 1 January 2019 was performed. Treatment success was defined as clinical response (significant improvement in UP-related symptoms) and endoscopic response (mayo endoscopic sub-score of 0 or 1) if available at last follow-up.
resultsFrom a total of 1561 patients with ulcerative colitis, 118 patients with UP were identified. A total of 36 (31%) patients were refractory to rectal and oral therapy with 5-ASA and corticosteroids, necessitating azathioprine as monotherapy in 19 (16%) patients and/or biological therapies in 33 (28%) patients. After a median follow-up of 71 months (interquartile range 29-149 months), treatment success was observed in 103/118 (87%) UP patients and in 25/36 (69%) patients with refractory UP. Clinical response rates were significantly higher for refractory UP patients treated with biologicals (23/33; 70%) compared to ones treated with azathioprine (2/19; 11%;
conclusionGood clinical outcomes were recorded in UP, with treatment success in 87% of patients. Nevertheless, 28% needed escalation to biologicals. Long-term outcome in patients on biologicals was superior to azathioprine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.